Ikena Oncology (NASDAQ:IKNA) Earns “Neutral” Rating from Wedbush

Ikena Oncology (NASDAQ:IKNA)‘s stock had its “neutral” rating restated by stock analysts at Wedbush in a report released on Monday,RTT News reports. They currently have a $2.00 target price on the stock. Wedbush’s price target indicates a potential upside of 30.72% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Ikena Oncology in a research note on Monday, November 11th.

Ikena Oncology Stock Down 8.4 %

IKNA stock opened at $1.53 on Monday. Ikena Oncology has a 52 week low of $1.22 and a 52 week high of $2.29. The company has a market cap of $73.83 million, a price-to-earnings ratio of -1.24 and a beta of 0.49. The business has a fifty day simple moving average of $1.69 and a 200-day simple moving average of $1.69.

Ikena Oncology (NASDAQ:IKNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.08. As a group, analysts expect that Ikena Oncology will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ikena Oncology

Several large investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC bought a new position in Ikena Oncology in the 2nd quarter worth approximately $30,000. BBR Partners LLC acquired a new stake in shares of Ikena Oncology in the second quarter worth $33,000. AQR Capital Management LLC bought a new position in Ikena Oncology during the second quarter worth $36,000. FMR LLC raised its stake in Ikena Oncology by 94.1% during the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after purchasing an additional 18,607 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Ikena Oncology in the 2nd quarter worth $75,000. Institutional investors own 75.00% of the company’s stock.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.